Natriuretic peptide infusion reduces myocardial injury during acute ischemia/reperfusion

Cardiovascular Endocrinology

Volumn 1, Issue 1, 2012, Pages 4-12

  Kousholt, Birgitte S ^a,b   Larsen, Jens K Rolighed ^a   Bisgaard, Line ^b   Burnett Jr , John C ^c   Hasenkam, John Michael ^a   Goetze, Jens P ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MAYO CLINIC   (United States)

Author keywords

BNP; CD NP; Ischemia reperfusion injury; Myocardial infarction; Porcine

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CASPASE 3; CASPASE 7; CYCLIC GMP; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; TROPONIN T; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL STIMULATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIURESIS; ENZYME ACTIVITY; EXPERIMENTAL PIG; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; IN VIVO STUDY; LUNG ARTERY PRESSURE; MEAN ARTERIAL PRESSURE; MOUSE; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SYSTEMIC CIRCULATION; VASODILATATION;

EID: 84889600415     PISSN: None     EISSN: 2162688X     Source Type: Journal    
DOI: 10.1097/XCE.0b013e328356c67b     Document Type: Article

References (34)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011; 123:e18-e209.
2. Simoons ML, Boersma E, Maas AC, Deckers JW. Management of myocardial infarction: the proper priorities. Eur Heart J 1997; 18: 896-899.
3. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, et al. Translating novel strategies for cardioprotection: the Hatter Workshop recommendations. Basic Res Cardiol 2010; 105: 677-686.
4. Martin FL, Chen HH, Cataliotti A, Burnett JC Jr. B-type natriuretic peptide: beyond a diagnostic. Heart Fail Clin 2008; 4: 449-454.
5. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004; 18: 1928-1930.
6. Munagala VK, Burnett JC Jr., Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707-769.
7. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, et al. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 2005; 115: 1666-1674.
8. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000; 97: 4239-4244.
9. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 1997; 94: 14730-14735.
10. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 2010; 56: 262-270.
11. Padilla F, Garcia-Dorado D, Agullo L, Barrabes JA, Inserte J, Escalona N, et al. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001; 51: 592-600.
12. Burley DS, Baxter GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007; 102: 529-541.
13. Hillock RJ, Frampton CM, Yandle TG, Troughton RW, Lainchbury JG, Richards AM. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008; 94: 617-622.
14. Lazar HL, Bao Y, Siwik D, Frame J, Mateo CS, Colucci WS. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg 2009; 24: 600-605.
15. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493.
16. Kato T, Muraski J, Chen Y, Tsujita Y, Wall J, Glembotski CC, et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005; 115: 2716-2730.
17. Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, et al. Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol 2010; 105: 643-650.
18. Laxson DD, Dai XZ, Schwartz JS, Bache RJ. Effects of atrial natriuretic peptide on coronary vascular resistance in the intact awake dog. J Am Coll Cardiol 1988; 11: 624-629.
19. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
20. Claycomb WC, Lanson NA Jr., Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95: 2979-2984.
21. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/ reperfusion injury. Circulation 2010; 121: 2012-2022.
22. Larsen JR, Aagaard SR, Hasenkam JM, Sloth E. Pre-occlusion ischaemia, not sevoflurane, successfully preconditions the myocardium against further damage in porcine in vivo hearts. Acta Anaesthesiol Scand 2007; 51: 402-409.
23. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981; 101: 593-600.
24. Hunter I, Rehfeld JF, Goetze JP. Measurement of the total proANP product in mammals by processing independent analysis. J Immunol Methods 2011; 370: 104-110.
25. Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med 2003; 3: 25-38.
26. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, et al. The RIN: a RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7:3.
27. Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, JimenezW. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol 2009; 297:H550-H555.
28. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49: 668-673.
29. Dickey DM, Burnett JC Jr., Potter LR. Novel bifunctional natriuretic peptides as potential therapeutics. J Biol Chem 2008; 283: 35003-35009.
30. McKie PM, Sangaralingham SJ, Burnett JC Jr., CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease. Curr Heart Fail Rep 2010; 7: 93-99.
31. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the working group of cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res 2010; 87: 406-423.
32. Baldwin WM III, Samaniego-Picota M, Kasper EK, Clark AM, Czader M, Rohde C, et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894-900.
33. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17: 1105-1107.
34. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-1929.